In postmenopausal patients, estrogens have an important role in breast cancer growth and aromatase inhibitors (AI) suppress the aromatase enzyme system which converts androgens into estrogens. The aim of this study was to evaluate the effect on estrogen suppression of formestane 250 mg i.m. fortnightly, given immediately after the failure of a previous treatment with non-steroidal AI. Twenty-two advanced breast cancer patients progressing on letrozole, anastrozole and aminoglutethimide entered the study. At the beginning of the study, the serum estrogen levels were suppressed by the previous treatment with non-steroidal AI, and the following treatment with formestane moderately maintained this suppression; in four patients serum estrogen levels increased fivefold after 10 weeks. Neither complete nor partial responses were observed; 11 patients (50%) showed a stable disease lasting ≥6 months, and the median time to progression was 6 months (range 3-9 months). No correlation was observed between clinical responses and serum estrogen suppression. Tolerability was satisfactory, and no patient withdrew from the study due to adverse events. In conclusion, formestane has demonstrated a moderate activity in estrogen suppression, and there is evidence that, at the failure of a previous treatment with non-steroidal AI, the sequential use of steroidal AI is feasible. This approach can be used in clinical practice in order to offer a disease control with a satisfactory quality of life

Zilembo, N., Bajetta, E., Bichisao, E., Martinetti, A., La Torre, I., Bidoli, P., et al. (2004). The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients. BIOMÉDECINE & PHARMACOTHÉRAPIE, 58(4), 255-259 [10.1016/j.biopha.2003.12.009].

The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients

Bidoli, P;
2004

Abstract

In postmenopausal patients, estrogens have an important role in breast cancer growth and aromatase inhibitors (AI) suppress the aromatase enzyme system which converts androgens into estrogens. The aim of this study was to evaluate the effect on estrogen suppression of formestane 250 mg i.m. fortnightly, given immediately after the failure of a previous treatment with non-steroidal AI. Twenty-two advanced breast cancer patients progressing on letrozole, anastrozole and aminoglutethimide entered the study. At the beginning of the study, the serum estrogen levels were suppressed by the previous treatment with non-steroidal AI, and the following treatment with formestane moderately maintained this suppression; in four patients serum estrogen levels increased fivefold after 10 weeks. Neither complete nor partial responses were observed; 11 patients (50%) showed a stable disease lasting ≥6 months, and the median time to progression was 6 months (range 3-9 months). No correlation was observed between clinical responses and serum estrogen suppression. Tolerability was satisfactory, and no patient withdrew from the study due to adverse events. In conclusion, formestane has demonstrated a moderate activity in estrogen suppression, and there is evidence that, at the failure of a previous treatment with non-steroidal AI, the sequential use of steroidal AI is feasible. This approach can be used in clinical practice in order to offer a disease control with a satisfactory quality of life
Articolo in rivista - Articolo scientifico
estrogens
English
2004
58
4
255
259
reserved
Zilembo, N., Bajetta, E., Bichisao, E., Martinetti, A., La Torre, I., Bidoli, P., et al. (2004). The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients. BIOMÉDECINE & PHARMACOTHÉRAPIE, 58(4), 255-259 [10.1016/j.biopha.2003.12.009].
File in questo prodotto:
File Dimensione Formato  
The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients.pdf

Solo gestori archivio

Dimensione 181.43 kB
Formato Adobe PDF
181.43 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/260467
Citazioni
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 10
Social impact